{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:26:30Z","timestamp":1785464790085,"version":"3.56.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Allergic rhinoconjunctivitis (ARC) is an allergic disease that is characterized by conjunctival and nasal symptoms such as edema and congestion of conjunctiva, rhinorrhea, sneezing, and blocked nose. Seasonal ARC (SARC) is usually induced by seasonal allergens and often occurs at specific times during the year. Traditional treatments of SARC include nasal corticosteroids, antihistamines, and mast cell membrane stabilizers. Biological agents such as omalizumab have also been proved effective in the treatment of SARC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aim to certify the preventative efficacy of omalizumab for SARC and explore its influence factors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medical records of 64 SARC patients were retrospectively analyzed, and generalized linear models were used to analyze influence factors of efficacy of omalizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with forepassed pollen season without omalizumab treatment, the combined symptom and medication score (CSMS) of ARC with pre-seasonal omalizumab was significantly lower (with omalizumab: 0.67[0.00,1.83], without omalizumab: 4.00[2.83,4.96], p&amp;lt;0.001, max score=6). Subgroup analysis was conducted to explore the influence factor of preventative efficacy of omalizumab. The CSMS with omalizumab treatment were not significantly different among different age, gender, dosage, number of injections, and injection date subgroups (p&amp;gt;0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Pre-seasonal omalizumab treatment could significantly relieve SARC related symptoms and reduce medication use. This preventative efficacy would not be influenced by the dosage and number of injections of omalizumab. A single dose of 150mg omalizumab could achieve a satisfactory outcome.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.913424","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:13:16Z","timestamp":1659003196000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Rui","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1055\/s-0034-1368397","article-title":"Seasonal and perennial allergic rhinoconjunctivitis","volume":"231","author":"Schr\u00f6der","year":"2014","journal-title":"Klin Monbl Augenheilkd"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.576039","article-title":"Impact of ocular symptoms on quality of life (QoL), work productivity and resource utilisation in allergic rhinitis patients\u2013an observational, cross sectional study in four countries in Europe","volume":"14","author":"Virchow","year":"2011","journal-title":"J Med Econ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.anai.2018.03.028","article-title":"The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents: A literature review","volume":"121","author":"Blaiss","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jaip.2016.10.010","article-title":"Findings from an online survey assessing the burden and management of seasonal allergic rhinoconjunctivitis in US patients","volume":"5","author":"Meltzer","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.clae.2011.08.009","article-title":"A review of non-pharmacological and pharmacological management of seasonal and perennial allergic conjunctivitis","volume":"35","author":"Bilkhu","year":"2012","journal-title":"Cont Lens Anterior Eye"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1185\/030079908x253780","article-title":"Evolving paradigm in the management of allergic rhinitis-associated ocular symptoms: role of intranasal corticosteroids","volume":"24","author":"Blaiss","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.2840","article-title":"Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis: A systematic review and meta-analysis","volume":"175","author":"Di Bona","year":"2015","journal-title":"JAMA Intern Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2020.01.004","article-title":"Roles of omalizumab in various allergic diseases","volume":"69","author":"Okayama","year":"2020","journal-title":"Allergol Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22827","article-title":"Impact of omalizumab on pollen-induced seasonal allergic rhinitis: An observational study in clinical practice","volume":"11","author":"Hirano","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"B10","article-title":"Guidelines for diagnosis and Treatment of Allergic rhinitis","volume-title":"Chinese J Otorhinolaryngol Head Neck Surg","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/all.12383","article-title":"Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper","volume":"69","author":"Pfaar","year":"2014","journal-title":"Allergy."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00138707","article-title":"Global strategy for asthma management and prevention: GINA executive summary","volume":"31","author":"Bateman","year":"2008","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.23.2956","article-title":"Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial","volume":"286","author":"Casale","year":"2001","journal-title":"Jama."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12094","article-title":"Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin Transl Allergy"},{"key":"B15","article-title":"Efficacy and safety of omalizumab for patients with hay fever and moderate or severe allergic asthma","volume":"25","author":"Tingting","year":"2018","journal-title":"Chinese J Otorhinolaryngol Head Neck Surg"},{"key":"B16","article-title":"Effect analysis of omalizumab in the treatment of allergic rhinitis with asthma","volume":"19","author":"Rui","year":"2021","journal-title":"J China Prescription Drug"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1248403","article-title":"Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma","volume":"12","author":"Luu","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/all.13345","article-title":"The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change","volume":"73","author":"Ertas","year":"2018","journal-title":"Allergy."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1016\/j.jaip.2020.03.051","article-title":"Aeroallergen sensitization, serum IgE, and eosinophilia as predictors of response to omalizumab therapy during the fall season among children with persistent asthma","volume":"8","author":"Sheehan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.04.002","article-title":"Omalizumab response in patients with asthma by number and type of allergen","volume":"127","author":"Soong","year":"2021","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.913424\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T10:13:21Z","timestamp":1659003201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.913424\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2022.913424"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.913424","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]},"article-number":"913424"}}